Press release
Myopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight
Myopia Clinical Trials
(Albany, USA) "Myopia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myopia Therapeutics Market.
As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 10+ pipeline drugs in the Myopia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
The report provides a detailed description of the Myopia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Myopia Clinical Trial Activities and Regulatory Developments in the domain @ Myopia Pipeline Outlook [https://www.delveinsight.com/report-store/myopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Myopia Pipeline Report
* DelveInsight's Myopia pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Myopia treatment.
* The leading Myopia Companies such as Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics, and others.
* Promising Myopia Therapies such as SYD-101 Dose 1, Alleance, NVK-002 Concentration 1, QLM3004 Concentration 1, Atropine Sulfate 01, and others.
* In March 2025, Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Arise, a lens fitting system that uses intelligent, cloud-based technology to streamline the orthokeratology lens design process. Arise seamlessly syncs directly with topographers - diagnostic tools that capture 3-D images of the eye - to create precise lens designs in seconds to treat myopia. These lenses include the first orthokeratology lens design with toric peripheral curves* approved by the U.S. Food and Drug Administration to treat myopia overnight.
* In March 2025, Sydnexis, Inc. a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for SYD-101 and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 23, 2025. If approved, SYD-101 would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States.
* In January 2025, ZEISS Medical Technology announced today that the MEL Registered 90 received approval from the U.S. Food and Drug Administration (FDA), giving the excimer laser technology simultaneous approval for all three major indications, including myopia, hyperopia and mixed astigmatism (a condition where both hyperopic and myopic correction is required). The ZEISS MEL 90 fully integrates into the Corneal Refractive Workflow to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX Registered 800 with SMILE Registered pro from ZEISS to help further broaden a surgeon's refractive business with improved patient attraction and positive clinical outcomes.
* July 2024:- Hoffmann-La Roche- This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).
* July 2024:- VIS Inc.- The goal of this clinical trial is to evaluate the safety and efficacy of using the VIS Opti-K System to enable monovision by providing temporary improvement in near vision through the treatment of the non-dominant eye of low myopic, emmetropic and low hyperopic presbyope subjects. The main questions it aims to answer are determining uncorrected near visual acuity at 40cm in the treated eye and subjective improvement as measured by the patient satisfaction questionnaire.
Myopia Pipeline Analysis
The report provides insights into:
* The report provides detailed insights into the key companies that are developing Myopia therapies.
* The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia treatment.
* It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* It navigates the emerging Myopia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Myopia treatment market.
Learn More about the Clinical and Commercial Development Activities in the Myopia Therapeutics Domain @ Myopia Clinical Trials and Advancements [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Myopia Therapeutics Analysis
Around 8+ prominent companies are actively engaged in the development of therapies for Myopia. Among these, Sydnexis stands out for advancing its Myopia drug candidates to the most advanced stage of clinical trials, specifically Phase III. This pivotal phase marks a critical milestone in the drug development journey, where the effectiveness and safety of the treatment are thoroughly evaluated in a larger patient population. Sydnexis's progress to Phase III underscores the potential significance of their therapeutic approach in addressing the challenges associated with Myopia, reflecting dedication and advancement within the field of ophthalmology and vision care.
Myopia Companies in the Therapeutics Market Include:
* Sydnexis
* Sunhawk Vision Biotech
* Vyluma
* Eyenovia
* Cloudbreak Therapeutics
* Stuart Therapeutics
And Many Others
Emerging and Marketed Myopia Therapies Covered in the Report Include:
* SYD-101 Dose 1
* Alleance
* NVK-002 Concentration 1
* QLM3004 Concentration 1
* Atropine Sulfate 01
* And Many Others
Get an in-depth Assessment of the Emerging Therapies and Myopia Companies Actively Working in the Market @ Myopia Medication and Manufacturers [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
The Myopia Pipeline report covers the Emerging Myopia Therapies under Different Phases of Clinical Development Like -
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued and inactive candidates
Myopia Route of Administration
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Myopia Molecule Type
Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Request for Sample PDF to Understand More About the Myopia Treatment Outlook and Future Perspectives @ Myopia Therapies and Drugs [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Myopia Current Treatment Patterns
4. Myopia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myopia Late-Stage Products (Phase-III)
7. Myopia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myopia Discontinued Products
13. Myopia Product Profiles
14. Myopia Companies
15. Myopia Drugs
16. Dormant and Discontinued Products
17. Myopia Unmet Needs
18. Myopia Future Perspectives
19. Myopia Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @ https://www.delveinsight.com/sample-request/myopia-pipeline-insight [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myopia-clinical-trials-analysis-2025-ema-pdma-fda-approvals-medication-therapies-nice-approvals-mechanism-of-action-roa-ind-nda-approval-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight here
News-ID: 3986017 • Views: …
More Releases from ABNewswire
Gerst Property Management Elevates Commercial Property Value with Innovative Str …
In the world of commercial real estate, the true measure of success isn't found solely in occupancy rates or rent rolls. It lies in the lasting value a property commands-today and tomorrow. Having worked across property and facilities management for more than two decades, and most recently preparing two commercial plazas for a successful sale to a development firm in 2022, We've seen firsthand how strategic management practices can elevate…
BTMarketing Unveils Key Trends Shaping the Future of Local SEO for Canadian Smal …
In digital marketing, I've always believed success is a marathon, not a sprint. Shortcuts may seem appealing, but they rarely deliver sustainable results. Much like choosing a scenic route over a busy highway, taking your time to do local SEO properly ensures a richer, more meaningful journey-and ultimately, lasting success.
Canadian small businesses face a uniquely competitive landscape. As the digital realm expands and evolves, local search visibility becomes a critical…
Converted Empowers B2C Businesses with Expert Conversion Strategies to Turn Visi …
Converted, a performance-driven digital agency based in the UK, is helping B2C companies across industries reach new heights by focusing on data-led strategies that attract more website visitors and turn them into loyal customers.
In today's fast-moving digital world, simply generating website traffic is no longer enough. Businesses must also ensure that this traffic leads to meaningful actions purchases, sign-ups, or inquiries. Converted specializes in this exact process, combining analytical insight…
The RTM Agency Launches AI-Powered RTM Clones
Content That Sounds Like You, Scales Like a Machine
Real talk: Most content out there? It's bland. Generic. Robotic. And it doesn't sell.
At RTM, we're not in the business of blending in.
We build Client Clones - AI-powered bots trained to write like our clients.
We call them RTM Clones. They speak your language, reflect your tone, and write with your brand's DNA baked in.
This isn't another AI shortcut. It's a revenue-generating asset.
What…
More Releases for Myopia
Adult Myopia Market Register to Healthy Growth through 2027
Adult myopia development is a common occurrence in practise, although there is little data to assist care. In this article, we'll look at how often and how much myopia progresses in adults, as well as treatment choices. We have some study data accessible on myopic teens and the stabilisation of their myopia development. Myopia stability and related variables among COMET trial participants, as well as the effects of discontinuing orthokeratology…
Myopia Management System Market Size | COVID-19 Impact Analysis | Forecast to 20 …
Myopia Management System market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market.
(Get 15% Discount on Buying this Report)
A full report of Global Myopia Management System Market is available at: https://www.orionmarketreports.com/myopia-management-system-market/49566/
The Myopia Management System key players in this market include:
• Zeiss International
• Essilor
• Bausch & Lomb
• Johnson & Johnson Vision
• Alcon Vision
• Topcon Corporation
• Haag-Streit…
Global Myopia Control Contact Lenses Market with Coronavirus (COVID-19) Impact A …
The research study presented here is an intelligent take on the global Myopia Control Contact Lenses market that explains important aspects such as competition, segmentation, and regional growth in great detail. Accuracy and preciseness are two of the key features of the report that reflect its authenticity. The authors of the report have focused on SWOT analysis, Porter’s Five Forces analysis, and PESTLE analysis of the global Myopia Control Contact Lenses market.…
Myopia Control Lens (Plastic Lens) Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Myopia Control Lens (Plastic Lens) market analysis, which studies the Myopia Control Lens (Plastic Lens)'s industry coverage, current market competitive status, and market outlook and forecast by 2025.
Global “Myopia Control Lens (Plastic Lens) Market 2020-2025” Research Report categorizes the global Myopia Control Lens (Plastic Lens) market by key players, product type, applications and regions,etc. The report…
Orthokeratology Market: Ortho-K May Gain Excellent Traction among Young Myopia P …
Orthokeratology has been considered to facilitate the elimination of contact lens related vision problems, providing patients with the freedom to experience an active lifestyle. While this factor will continue to play a pivotal role in growing adoption of Ortho-K lenses, Future Market Insights has discovered a few other factors that are likely to impact the growth of orthokeratology market in near future. In a recently released report, titled “Orthokeratology Market: Global Industry…
Orthokeratology (Ortho-K) Market Demand Getting High Rise Due to Increasing Prev …
Orthokeratology (Ortho-K) is a non-surgical procedure using specially designed contact lenses to gently reshape the curvature of the eye to improve vision. It is most frequently used to temporarily correct myopia (near-sightedness). Ortho-k can correct upwards of -6.00 diopters (D) of myopia. It is also useful in correction of lesser degrees of astigmatism, presbyopia and hyperopia. Overnight ortho-K lenses are most commonly used in comparison to daytime wear. According to…
